Chapter 4: Introduction to Autonomic Pharmacology — Module 1: Organization and Functional Anatomy of the Autonomic Nervous System Tier 1 — Foundational Recall — 8 questions
1. Which of the following best defines the primary functional scope of the autonomic nervous system as it applies to pharmacological targeting?
A) The ANS governs voluntary control of skeletal muscle contraction through alpha motor neurons originating in the anterior horn of the spinal cord -- autonomic pharmacology therefore targets the neuromuscular junction and the motor end plate as its principal sites of drug action.
B) The ANS governs conscious modulation of somatic sensation through dorsal column pathways and the thalamus -- autonomic drugs act primarily by altering sensory thresholds at spinal cord relay nuclei rather than by targeting effector organs.
C) The ANS governs involuntary regulation of smooth muscle, cardiac muscle, and glandular secretion -- autonomic pharmacological agents achieve their therapeutic effects by targeting the receptors, neurotransmitters, and signal transduction pathways that control these visceral functions.
D) The ANS governs integration of proprioceptive signals from joints and tendons through the spinocerebellar tracts -- autonomic pharmacology therefore targets the cerebellum and basal ganglia as its primary sites of drug action.
E) The ANS governs transmission of visceral pain signals from abdominal organs to the cortex via the thalamus exclusively -- autonomic drugs act as analgesics by blocking afferent pain transmission rather than by modifying efferent motor output to visceral effector organs.
ANSWER: C
Rationale:
The autonomic nervous system governs involuntary visceral function, acting on smooth muscle (blood vessels, bronchi, GI tract, bladder, uterus), cardiac muscle (rate, conduction, contractility), and exocrine and endocrine glands (salivary, lacrimal, sweat, digestive). This foundational definition determines which organ systems and receptor types are targeted by autonomic pharmacological agents. Voluntary skeletal muscle control, somatic sensation, and proprioception are functions of the somatic nervous system, entirely separate from the ANS. Options D and E describe specific neural pathways that are not the primary targets of autonomic pharmacology.
Option A: Option A describes the somatic motor system.
Option B: Option B describes the somatic sensory system.
2. Which of the following correctly identifies the spinal cord region of origin for sympathetic preganglionic neurons and the anatomical designation that derives from this location?
A) Sympathetic preganglionic neurons originate in the intermediolateral cell column spanning T1 through L2-L3 -- this origin gives rise to the designation thoracolumbar outflow, reflecting the thoracic and upper lumbar spinal cord segments from which all sympathetic preganglionic fibers arise.
B) Sympathetic preganglionic neurons originate in the anterior horn spanning C5 through T1 -- this origin gives rise to the designation cervicothoracic outflow and explains why cervical cord injuries always abolish all sympathetic function bilaterally while preserving parasympathetic function entirely.
C) Sympathetic preganglionic neurons originate in the dorsal horn spanning S2 through S4 -- this origin gives rise to the designation sacral outflow and accounts for the characteristic pelvic distribution of sympathetic effector organs including the bladder, rectum, and reproductive organs.
D) Sympathetic preganglionic neurons originate in Clarke's nucleus spanning T1 through L2 -- Clarke's nucleus serves as the integration center for both sympathetic preganglionic outflow and spinocerebellar tract neurons, explaining the association between spinal cord injury and autonomic dysfunction.
E) Sympathetic preganglionic neurons originate in the intermediolateral cell column spanning S2 through S4 -- this origin gives rise to the designation sacrosacral outflow and is the basis for the effectiveness of sacral spinal cord stimulation in treating sympathetically-mediated chronic pain.
ANSWER: A
Rationale:
Sympathetic preganglionic neurons originate in the intermediolateral (IML) cell column of the spinal cord, spanning from T1 to L2-L3. This anatomical origin is the basis for the designation thoracolumbar outflow. The preganglionic axons exit via the ventral roots and travel through the white rami communicantes to reach the paravertebral sympathetic chain. Options C and E both incorrectly assign sacral segments to the sympathetic division -- S2-S4 is the origin of parasympathetic preganglionic neurons (the sacral component of the craniosacral outflow). Clarke's nucleus (option D) gives rise to the spinocerebellar tract, not the sympathetic outflow. The anterior horn (option B) contains somatic motor neurons.
3. The term craniosacral outflow designates the anatomical origin of which division of the autonomic nervous system, and which cranial nerves carry the cranial component of this outflow?
A) The sympathetic division -- the cranial component of the thoracolumbar outflow travels within the trigeminal nerve (CN V) to reach the head and neck, while the sacral component originates in S2-S4 and supplies the pelvic viscera; together these constitute the craniosacral distribution of sympathetic innervation.
B) The enteric division -- the craniosacral outflow refers to the two plexuses of the enteric nervous system, with the cranial component (myenteric plexus) supplied by vagal fibers and the sacral component (submucosal plexus) supplied by pelvic splanchnic nerves from S2-S4.
C) The somatic motor division -- the craniosacral designation reflects the fact that somatic motor neurons arise from both the brainstem (cranial motor nerves CN III, IV, VI, VII, IX, X, XI, XII) and the sacral spinal cord (pudendal nerve for external urethral and anal sphincters), with the remaining somatic outflow from cervical, thoracic, and lumbar segments.
D) The parasympathetic division -- the cranial component arises from preganglionic neurons in four cranial nerve nuclei: the Edinger-Westphal nucleus (CN III), superior and inferior salivatory nuclei (CN VII and CN IX), and the dorsal motor nucleus and nucleus ambiguus (CN X); the sacral component arises from the intermediolateral cell column at S2-S4, with preganglionic fibers forming the pelvic splanchnic nerves.
E) The sympathoadrenal axis -- the cranial component consists of preganglionic fibers traveling within CN X to directly innervate the adrenal medulla without synapsing in any peripheral ganglion, while the sacral component provides preganglionic innervation to pelvic sympathetic ganglia via the pelvic splanchnic nerves.
ANSWER: D
Rationale:
The parasympathetic division is designated the craniosacral outflow because its preganglionic neurons arise from two spatially separated regions: cranial nerve nuclei in the brainstem and the IML at S2-S4. The cranial component is carried by four cranial nerves: CN III (Edinger-Westphal nucleus to ciliary ganglion -- ciliary muscle and sphincter pupillae); CN VII (superior salivatory nucleus to pterygopalatine and submandibular ganglia -- lacrimal gland and salivary glands); CN IX (inferior salivatory nucleus to otic ganglion -- parotid gland); and CN X (dorsal motor nucleus and nucleus ambiguus to terminal ganglia within thoracic and abdominal viscera). The vagus carries approximately 75% of total parasympathetic preganglionic output. The sacral component (pelvic splanchnic nerves from S2-S4) supplies the distal colon, rectum, bladder, and reproductive organs. The sympathetic division is the thoracolumbar outflow -- not craniosacral.
4. Which of the following correctly identifies the two named plexuses of the enteric nervous system and their respective primary functional roles?
A) The brachial plexus (C5-T1) governs motor output to upper extremity smooth muscle vasculature, while the lumbosacral plexus (L1-S3) governs motor output to lower extremity vasculature -- together they constitute the enteric nervous system responsible for peripheral vascular resistance regulation.
B) The myenteric (Auerbach's) plexus lies between the longitudinal and circular muscle layers of the GI tract and governs primarily gastrointestinal motility; the submucosal (Meissner's) plexus lies in the submucosa and governs primarily local blood flow, epithelial secretion, and absorption -- together they comprise the enteric nervous system, which contains an estimated 200–600 million neurons and can sustain coordinated GI function independent of extrinsic ANS input.
C) The celiac plexus lies anterior to the aorta at L1 and governs GI motility throughout the small and large intestine, while the hypogastric plexus governs urogenital function -- together these prevertebral sympathetic ganglia constitute the enteric plexuses responsible for abdominal visceral innervation.
D) The submucosal plexus lies between the longitudinal and circular muscle layers and governs GI motility as the primary motor plexus, while the myenteric plexus lies in the submucosa and governs secretion and absorption -- the reversed anatomical positions of these two plexuses relative to their functional roles is a common source of confusion in autonomic pharmacology examinations.
E) The solar plexus (celiac-aortic plexus) governs digestion by distributing sympathetic postganglionic fibers to all abdominal organs, while the cardiac plexus governs heart rate by distributing both sympathetic and parasympathetic fibers to the sinoatrial and atrioventricular nodes -- together these constitute the two divisions of the enteric nervous system.
ANSWER: B
Rationale:
The enteric nervous system (ENS) consists of two interconnected neural plexuses embedded within the wall of the gastrointestinal tract. The myenteric (Auerbach's) plexus lies between the longitudinal and circular muscle layers and governs GI motility, coordinating peristaltic reflexes and the migrating motor complex. The submucosal (Meissner's) plexus lies in the submucosa and governs local blood flow, epithelial secretion, and absorption. The ENS contains an estimated 200-600 million neurons and can sustain coordinated GI function in the complete absence of extrinsic autonomic input, as demonstrated by the persistence of intestinal peristalsis in transplanted bowel. option C) are prevertebral sympathetic ganglia, not ENS structures.
Option D: Option D reverses the anatomical locations of the two plexuses -- a specifically designed distractor targeting this common error. The celiac and hypogastric plexuses (
5. Which pharmacological agent is used to confirm the diagnosis of Horner syndrome, and what is the mechanism by which it does so?
A) Systemic atropine administration produces the full Horner triad (ptosis, miosis, and anhidrosis) by blocking M3 muscarinic receptors at the iris sphincter pupillae, superior tarsal muscle, and facial sweat glands -- atropine is therefore used diagnostically to produce reversible pharmacological Horner syndrome in the contralateral eye for comparison.
B) Topical pilocarpine 0.1% reproduces the miosis component of Horner syndrome by activating M3 muscarinic receptors on the iris sphincter pupillae -- this pharmacological miosis is used to distinguish Horner syndrome from other causes of anisocoria, since a denervated iris sphincter shows supersensitivity to dilute pilocarpine and constricts at lower concentrations than the normal contralateral eye.
C) Topical hydroxyamphetamine 1% is the definitive confirmatory test for all Horner syndrome regardless of lesion location -- it dilates the Horner pupil in all three neuron levels by releasing stored norepinephrine from any remaining sympathetic terminal, producing dilation equal to that seen in the normal fellow eye; failure to dilate confirms the pupil is pharmacologically unresponsive regardless of which neuron is disrupted.
D) Topical cocaine 4-10% confirms the diagnosis of Horner syndrome by failing to dilate the affected pupil -- cocaine blocks norepinephrine reuptake at intact postganglionic sympathetic terminals, accumulating NE at the iris dilator alpha-1 receptor and producing mydriasis in the normal eye; in any Horner syndrome at any neuron level, the sympathetic pathway is interrupted and cocaine fails to dilate the affected pupil, confirming sympathetic disruption.
E) Topical phenylephrine 10% reproduces the ptosis component of Horner syndrome by activating M3 muscarinic receptors at the superior tarsal muscle -- phenylephrine is used therapeutically to reverse ptosis in confirmed Horner syndrome by restoring adrenergic tone to the superior tarsal (Muller's) muscle.
ANSWER: D
Rationale:
Cocaine eye drops (4-10%) block the norepinephrine transporter (NET) at postganglionic sympathetic terminals innervating the iris dilator pupillae, preventing reuptake of tonically released NE and allowing it to accumulate at the alpha-1 receptor, producing mydriasis. For cocaine to produce dilation, the postganglionic terminal must be intact and releasing NE tonically. In any Horner syndrome -- first, second, or third order neuron interruption -- the sympathetic pathway is disrupted and cocaine fails to dilate the affected pupil. Cocaine therefore confirms Horner syndrome is present but does not localize the level of the lesion. Hydroxyamphetamine 1% (
Option C: option C is incorrect as stated -- it dilates only first- and second-order lesions where the third-order neuron is intact, not all Horner syndrome levels) is used as a secondary test to localize the lesion.
Option E: Option E incorrectly attributes phenylephrine's mechanism to muscarinic receptors -- phenylephrine is a direct alpha-1 adrenergic agonist.
6. The term ganglionic blocker refers to a drug that interrupts transmission at which anatomical site, and which clinically used agents exemplify this class?
A) Ganglionic blockers interrupt transmission at the postganglionic adrenergic nerve terminal by preventing norepinephrine release through blockade of voltage-gated calcium channels -- guanethidine and bretylium are the prototype agents, acting as false transmitters that are taken up into sympathetic nerve terminals and displace norepinephrine from vesicular stores.
B) Ganglionic blockers interrupt transmission at the effector organ muscarinic receptor by competitive antagonism of acetylcholine binding -- atropine and scopolamine are the prototypical agents, blocking M2 and M3 receptors at cardiac, smooth muscle, and glandular effector sites simultaneously.
C) Ganglionic blockers interrupt transmission at the autonomic ganglion nicotinic (NN) receptor, blocking fast excitatory synaptic transmission between preganglionic and postganglionic neurons -- because NN receptors are present in both sympathetic and parasympathetic ganglia, ganglionic blockade interrupts both divisions simultaneously; trimethaphan and hexamethonium are prototypical agents, producing a combined sympatholytic and parasympatholytic profile.
D) Ganglionic blockers interrupt transmission at the neuromuscular junction nicotinic (NM) receptor, producing non-depolarizing competitive blockade of skeletal muscle contraction -- tubocurarine, vecuronium, and rocuronium are prototypical agents used in anesthesia to provide surgical muscle relaxation without affecting autonomic ganglionic transmission.
E) Ganglionic blockers interrupt transmission at the central sympathetic nucleus in the RVLM by acting as alpha-2 adrenergic agonists that reduce brainstem sympathetic outflow -- clonidine and methyldopa are prototypical agents that lower blood pressure by reducing central preganglionic neuron firing rather than by blocking peripheral ganglionic transmission directly.
ANSWER: C
Rationale:
Ganglionic blockers act at the autonomic ganglion nicotinic (NN) receptor -- pentameric ligand-gated ion channels composed predominantly of alpha3 and beta4 subunits, pharmacologically distinct from NM receptors at the neuromuscular junction. Because NN receptors are present in both sympathetic and parasympathetic ganglia, ganglionic blockade interrupts both divisions simultaneously, producing a combined sympatholytic and parasympatholytic profile. The expected effects reflect loss of each division's resting dominant tone: hypotension (loss of sympathetic alpha-1 vascular tone), tachycardia (loss of dominant resting vagal tone at the SA node), mydriasis and cycloplegia (loss of parasympathetic M3-mediated pupillomotor tone), dry mouth, urinary retention, constipation, and anhidrosis. Trimethaphan (IV, used historically for hypertensive emergencies) and hexamethonium (research tool) are the prototypical agents. Option D correctly describes neuromuscular blockers, a distinct class acting at NM rather than NN receptors.
Option E: Option E describes centrally acting sympatholytics, not ganglionic blockers.
7. Which of the following best defines the term preganglionic fiber in autonomic neuroanatomy and identifies the neurotransmitter released at the preganglionic synapse for both sympathetic and parasympathetic divisions?
A) A preganglionic fiber is a neuron whose cell body lies in the CNS (brainstem or spinal cord) and whose axon synapses on a postganglionic neuron within an autonomic ganglion -- the neurotransmitter released by preganglionic fibers is acetylcholine in both the sympathetic and parasympathetic divisions, acting on nicotinic (NN) receptors at the postganglionic cell body; this shared nicotinic transmission at all autonomic ganglia is why ganglionic blockers (trimethaphan, hexamethonium) interrupt both divisions simultaneously regardless of which division is being therapeutically targeted.
B) A preganglionic fiber is a neuron whose cell body lies within the autonomic ganglion and whose axon travels to the target effector organ -- the neurotransmitter released by postganglionic sympathetic fibers is norepinephrine (acting on alpha and beta adrenergic receptors) while postganglionic parasympathetic fibers release acetylcholine (acting on muscarinic receptors).
C) A preganglionic fiber is an afferent (sensory) neuron that carries visceral sensory information from peripheral organs back to the central nervous system via the nucleus tractus solitarius -- these fibers release glutamate at their central synapse and constitute the afferent limb of autonomic reflex arcs including the baroreceptor reflex.
D) A preganglionic fiber is a somatic motor neuron that exits the ventral root and travels to the autonomic ganglion before reaching its final target in the skeletal muscle motor end plate -- the preganglionic fiber therefore constitutes the first neuron in the two-neuron somatic motor pathway.
E) A preganglionic fiber is a fiber that transmits pain signals from visceral organs through the dorsal root ganglion to the spinal cord -- the preganglionic designation refers to the fiber's position before the dorsal root ganglion cell body, and it releases substance P and CGRP at its central terminal in the dorsal horn.
ANSWER: A
Rationale:
Preganglionic neurons have their cell bodies in the CNS -- in the IML for sympathetic preganglionic neurons, and in brainstem cranial nerve nuclei or S2-S4 for parasympathetic preganglionic neurons. Their axons travel to synapse on postganglionic neurons within an autonomic ganglion. A critical pharmacological fact: both sympathetic AND parasympathetic preganglionic fibers release acetylcholine as their neurotransmitter, acting on nicotinic NN receptors at the postganglionic cell body. This shared nicotinic transmission at all autonomic ganglia is why ganglionic blockers interrupt both divisions simultaneously. The distinction between sympathetic and parasympathetic occurs at the postganglionic-to-effector synapse: sympathetic postganglionic fibers release norepinephrine (acting on adrenergic receptors), while parasympathetic postganglionic fibers release ACh (acting on muscarinic receptors). Important exception: sympathetic postganglionic fibers to sweat glands release ACh despite being anatomically sympathetic.
Option B: Option B describes the postganglionic fiber, not the preganglionic fiber.
8. Which cranial nerve carries approximately 75% of the total parasympathetic preganglionic output, and which specific organ systems does it innervate through terminal ganglia?
A) The glossopharyngeal nerve (CN IX) carries 75% of parasympathetic preganglionic output -- it innervates the parotid gland, lacrimal gland, submandibular gland, sublingual gland, and all thoracic and abdominal viscera as far as the transverse colon through the otic ganglion.
B) The facial nerve (CN VII) carries 75% of parasympathetic preganglionic output -- it innervates the lacrimal gland, nasal mucosa, submandibular gland, sublingual gland, heart, lungs, esophagus, and small intestine through the pterygopalatine and submandibular ganglia.
C) The oculomotor nerve (CN III) carries 75% of parasympathetic preganglionic output -- it innervates the sphincter pupillae, ciliary muscle, lacrimal gland, and all thoracic and abdominal viscera through the ciliary ganglion's extensive peripheral connections to the pterygopalatine and otic ganglia.
D) The trigeminal nerve (CN V) carries 75% of parasympathetic preganglionic output -- it carries postganglionic parasympathetic fibers from the pterygopalatine, submandibular, and otic ganglia to the lacrimal gland, salivary glands, and nasal mucosa, functioning as the primary distribution nerve for all cranial parasympathetic postganglionic output.
E) The vagus nerve (CN X) carries approximately 75% of total parasympathetic preganglionic output -- its preganglionic fibers originate from the dorsal motor nucleus and nucleus ambiguus in the medulla and travel to terminal ganglia embedded within or immediately adjacent to the thoracic and abdominal viscera, innervating the heart (SA and AV nodes), lungs, esophagus, stomach, small intestine, and proximal large intestine as far as the splenic flexure.
ANSWER: E
Rationale:
The vagus nerve (CN X) carries approximately 75% of total parasympathetic preganglionic output, making it by far the most important parasympathetic nerve in the body. Its preganglionic fibers originate from the dorsal motor nucleus of the vagus (supplying subdiaphragmatic viscera) and the nucleus ambiguus (supplying the heart). Vagal terminal ganglia are embedded within or immediately adjacent to the target organs, reflecting the characteristic long-preganglionic/short-postganglionic architecture of the parasympathetic division. Target organs include the heart (SA and AV nodes -- mediating resting vagal bradycardia), lungs (bronchial smooth muscle and mucous glands -- mediating resting bronchomotor tone), esophagus, stomach, small intestine, and proximal large intestine to the splenic flexure. CN IX innervates only the parotid gland; CN VII serves the lacrimal and submandibular/sublingual salivary glands; CN III serves the ciliary and sphincter pupillae via the ciliary ganglion. CN V (option D) carries postganglionic parasympathetic fibers as a distribution highway but has no preganglionic parasympathetic cell bodies of its own.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.